trending Market Intelligence /marketintelligence/en/news-insights/trending/umvw752e6pnypzwohhqvra2 content esgSubNav
In This List

Lilly to acquire pain drug program from Hydra Biosciences

Blog

Funding Social and Affordable Housing: A Credit Perspective

Blog

Global Capital Markets & SPAC Activity – H1 2021

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals


Lilly to acquire pain drug program from Hydra Biosciences

Eli Lilly and Co. will acquire a preclinical pain drug program from Hydra Biosciences Inc.

The Indianapolis-based company will acquire all assets related to Cambridge, Mass.-based Hydra's pre-clinical program related to the transient receptor potential ankyrin 1, or TRPA1, inhibiting drugs.

TRPA1 is a protein whose function includes an electrical signaling, among others, and is responsible for sensations of pain, pressure and warmth, among other things. Hydra's program is aimed at developing drugs that inhibit these proteins and act as a potential treatment of chronic pain syndromes.

Financial terms of the transaction were not disclosed.

Lilly said the transaction will have no change to its non-GAAP per share guidance for 2018.